IP Library Granted Patent US 7,601,758
Granted Patent B1
US 7,601,758 · App. 12/368,700 · Granted Oct 13, 2009

Methods for concomitant administration of colchicine and macrolide antibiotics in the treatment of gout flares

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,601,758
App. No.
12/368,700
Granted
Oct 13, 2009
Kind
B1
Abstract

Methods for treating gout flares comprising concomitant administration of colchicine together with one or more macrolide antibiotics, e.g., clarithromycin or erythromycin, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. Methods of notifying health care practitioners and patients regarding appropriate dosing for co-administration of colchicine together with macrolide antibiotics are also provided.

Claims (18)

1. A method of using colchicine to treat a gout flare in a human patient who is receiving concomitant administration of clarithromycin or erythromycin, said method comprising:

determining a first colchicine dosage amount adapted for oral administration to the patient to treat a gout flare in the absence of concomitant administration of clarithromycin or erythromycin,

determining a second colchicine dosage amount that is about a two thirds reduction of the first colchicine dosage amount,

orally administering the second colchicine dosage amount to the patient who is experiencing a gout flare and is concomitantly receiving administration of clarithromycin or erythromycin, wherein concomitant administration of clarithromycin or erythromycin is administration within 1 to 2 days of orally administering the second colchicine dosage amount, and

not repeating colchicine administration for at least three days.

2. The method of claim 1 wherein the two thirds reduction comprises reducing the number of doses of colchicine administered.

3. The method of claim 1 wherein the two thirds reduction comprises reducing the size of at least one colchicine dose.

4. The method of claim 1 wherein the two thirds reduction comprises reducing both the number of doses of colchicine administered and the size of at least one colchicine dose.

5. The method of claim 1 wherein the patient is an adult.

6. The method of claim 5 wherein the patient is less than 70 years old.

7. The method of claim 1 wherein the patient is receiving concomitant administration of clarithromycin.

8. The method of claim 1 wherein the first colchicine dosage amount is about 1.8 mg per day and the second colchicine dosage amount is about 0.6 mg per day.

9. The method of claim 8 wherein, after administration of the second colchicine dosage amount as a single 0.6 mg dose, ingestion of colchicine is not repeated for at least three days.

10. A method of using colchicine to treat a gout flare in an adult human gout patient so as to reduce the occurrence of colchicine toxicity when said patient is receiving concomitant administration of clarithromycin or erythromycin, said method comprising:

administering a reduced colchicine dosage amount to the patient to treat gout flares, wherein the reduced colchicine dosage amount is about 50% to about 75% of a manufacturer's recommended colchicine dosage amount in the absence of concomitant clarithromycin or erythromycin administration, and

not repeating colchicine administration for at least three days,

wherein concomitant administration of clarithromycin or erythromycin is administration within 1 to 2 days of orally administering the second colchicine dosage amount.

11. The method of claim 10 wherein the reduced colchicine dosage amount is about 0.6 mg per day.

Assignments (8)
MERGER Recorded Nov 30, 2012
From: AR HOLDING COMPANY, INC.
To: MPC OLDCO, INC.
Reel/Frame 029378/0850 →
MERGER Recorded Nov 30, 2012
From: MPC OLDCO, INC.
To: MPC MERGER SUB, INC.
Reel/Frame 029380/0671 →
MERGER Recorded Nov 30, 2012
From: MPC MERGER SUB, INC.
To: TAKEDA PHARMACEUTICALS U.S.A., INC.
Reel/Frame 029380/0855 →
RELEASE OF SECURITY INTEREST Recorded Aug 15, 2011
From: UBS AG, STAMFORD BRANCH, A SWISS BANKING INSTITUTION
To: MUTUAL PHARMACEUTICAL COMPANY, INC., A PENNSYLVANIA CORPORATION
Reel/Frame 026748/0397 →
RELEASE OF SECURITY INTEREST Recorded Aug 4, 2011
From: UBS AG, STAMFORD BRANCH, A SWISS BANKING INSTITUTION
To: MUTUAL PHARMACEUTICAL COMPANY, INC., A PENNSYLVANIA CORPORATION
Reel/Frame 026700/0240 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 1, 2009
From: MUTUAL PHARMACEUTICAL COMPANY, INC.
To: AR HOLDING COMPANY, INC.
Reel/Frame 023583/0870 →
PATENT SECURITY AGREEMENT Recorded Apr 8, 2009
From: MUTUAL PHARMACEUTICAL COMPANY, INC.
To: UBS AG, STAMFORD BRANCH, AS COLLATERAL AGENT
Reel/Frame 022523/0838 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 18, 2009
From: DAVIS, MATTHEW W.
To: MUTUAL PHARMACEUTICAL COMPANY, INC.
Reel/Frame 022274/0068 →